Company Update: SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM |
Learn More
Search for:
About us
Leadership team
Direction and location
Code of Conduct and Ethics
Our new 5,000 m2 biomanufacturing site
Services
Bioprocess development (USP & DSP)
cGMP manufacturing of clinical & commercial batches
Analytical Development, Qualification & Validation – QC & QA
Fill & Finish
Regulatory Support
Our platforms
LentiSure™: Lentivirus Manufacturing Platform
AAVelocity™: AAV Manufacturing Platform
Innovation
News, blog & events
News
Blog
Events
Careers
Contact us
Search for:
News
All
News
Blog
Events
Yposkesi launches AAVelocity™, a plug-and-play Adeno-Associated Virus (AAV) platform
7 November 2023
Read more
SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in Center for Breakthrough Medicines
20 September 2023
Read more
Yposkesi inaugurates €60M biomanufacturing site for cell and gene therapies
22 June 2023
Read more
‘Choose France’ Yposkesi welcomes French Ministers to newly constructed 5,000m2 site – under government scheme
15 May 2023
Read more
Yposkesi launches LentiSure™, Lentiviral (LV) Vector production platform optimized for higher yields
5 April 2023
Read more
Yposkesi reinforces team with three executive appointments
12 July 2022
Read more
ASMA Consortium: Improving access to innovative bio therapeutics through acoustic technologies
22 February 2022
Read more
Yposkesi launches construction of its second bioproduction site.
14 June 2021
Read more
Yposkesi welcomes SK Group as new majority equity shareholder, forging solid industrial partnership for growth.
31 March 2021
Read more
Apres le Génopole, Novartis choisit l’Essonne pour ses therapies géniques
9 December 2020
Read more
Load more News
Would you like to know more ?
Contact us